DSwiss, Inc.(DQWS.US)

Company Encyclopedia

DSwiss, Inc.

DQWS.US

DSwiss, Inc., a biotech nutraceutical company, provides healthcare, skincare, and personal care products in Malaysia, Singapore, Indonesia, Australia, Hong Kong, Taiwan, Macau, and China. It supplies health and beauty products, including beverages to assist in weight management, anti-aging creams, and products designed to enhance the health system in body. The company also provides private label manufacturing services for nutraceutical and skincare/personal care ODM/OEM products; pet wellness supplements; and pet-care products, as well as medical consumable supplies. Further, it offers OEM/ODM/OBM services; and biotechnology research channel services.

552.12 B

DQWS.USMarket value -Rank by Market Cap -/-

Financial Score

07/02/2026 Update

Personal Care ProductsIndustry

Industry Ranking38/57

Industry medianC

Industry averageC

Score Analysis

Peer Comparison

Criteria
Rating
Profit ScoreD
- ROE-24.28%E
- Profit Margin-1.20%D
- Gross Margin13.26%D
Growth ScoreB
- Revenue YoY39.89%A
- Net Profit YoY-158.75%E
- Total Assets YoY-1.99%D
- Net Assets YoY-25.18%E
Cash ScoreC
- Cash Flow Margin-8302.11%E
- OCF YoY39.89%A
Operating ScoreA
- Turnover4.33A
Debt ScoreE
- Gearing Ratio81.44%E

Valuation analysis

P/E

10Y

P/E

Industry Ranking

-/-

P/E
Price
High
Median
Low

P/B

10Y

P/B

Industry Ranking

-/-

P/B
Price
High
Median
Low

P/S

10Y

P/S

Industry Ranking

-/-

P/S
Price
High
Median
Low

Dividend Yield

10Y

Dividend Yield

Industry Ranking

-/-

Dividend Yield
Price
High
Median
Low

Institutional View & Shareholder

Analyst Ratings

Rating

Percentage

Price
--
Highest
--
Lowest
--

Shareholder

Ownership	%Owned	Share Chg	Report Date
Ming Chia Leong	30.4%	No Change	31/12/2024
Jen Jiang Teo	21.27%	No Change	31/12/2024
Yuen Foong Hew	15.95%	No Change	31/12/2024
Kock Yong Siow	15.89%	No Change	31/12/2024
Greenpro Venture Capital Limited	7.33%	No Change	31/12/2024
Sui Ting Wong	0.02%	No Change	31/12/2024

News

Dan Bin: We are still in a year of significant development for artificial intelligence. Even if stocks decline this year, the bubble is just noise. Focus on the supply chains of NVIDIA, Google, and Tesla

Dan Bin shared his market investment insights on the era of artificial intelligence in a CCTV finance program. He believes that we are still in a year of significant development for artificial intelligence. Despite the stock market decline, he views the bubble as mere noise and advises investors to focus on industry chains such as NVIDIA, Alphabet, and Tesla. He emphasized that the risk of missing out on the era is greater than the concern about the bubble, recommending that funds be directed towards emerging industries like artificial intelligence and biopharmaceuticals, and he believes the next decade will be a bull market for artificial intelligence

Wallstreetcn·02/06/2026 13:48

Innovation and Technology Bureau: The government has supported over 500 innovation and technology enterprises to develop in Hong Kong since 2023

The Secretary for Innovation, Technology and Industry, Sun Dong, stated that since 2023, the government has supported over 500 innovation and technology enterprises to develop in Hong Kong, covering fields such as life and health technology, artificial intelligence, and robotics. A HKD 180 million "Innovation and Technology Accelerator Pilot Program" has been launched to attract professional service organizations to establish accelerator bases to support startups. At the same time, a HKD 3 billion "Frontier Technology Research Support Program" aims to attract international technology talent. The Hong Kong Science Park in the Lok Ma Chau Loop has opened, with 60 technology companies signing up to settle there, and the second phase of the development plan has been completed, providing 2 million square meters of floor area. The government will promote the phased development of the San Tin Technology City

AASTOCKS·02/05/2026 09:30

"Hong Kong Stocks" Hang Seng Index rises 12 points, software and tech stocks under pressure, coal and domestic property stocks rise

The Hong Kong stock market showed mixed performance, with the Hang Seng Index rising 12 points to 26,847 points, the Hang Seng China Enterprises Index falling 4 points, and the Hang Seng TECH Index dropping 100 points. Software and technology stocks were under pressure, with Tencent and NETEASE falling by 3% to 4%, and AI-related stocks were also affected. Coal and domestic property stocks performed better. The total market turnover decreased to HKD 285.433 billion

AASTOCKS·02/04/2026 16:36

Beigene (6160.HK): Range-bound fluctuations, cautious and repetitive capital, the game in the pharmaceutical sector becomes complex before new regulations

On February 3rd, BeiGene experienced significant fluctuations throughout the day, opening high and then pulling back. Although funds were somewhat active in the short term, supporting a slight rebound, the overall trend showed weakness. Currently, the pharmaceutical sector is relatively mild, with the market rebound attracting some long-term funds to test the waters. The main operators displayed clear hesitation and repetition, with the day's rhythm primarily characterized by strong fluctuations. Recently, the market has focused on news such as "new contracts in the CXO business," which has activated short-term funds related to pharmaceuticals. However, despite increased trading volume, the main funds are still primarily engaged in range trading, leading to intensified overall bullish-bearish divergence and a strong wait-and-see atmosphere. The MACD daily signal has shown some phase repair, but the resistance area above the stock price and long-term pressure remain heavy, with no clear signs of sustained upward movement from the main operators. On the news front, there are currently no major disturbances in the pharmaceutical sector, and the rotation of themes and active funds have revealed structural opportunities. The intraday performance showed a high opening and pullback, with multiple tests of the 20-day moving average. Right-side funds dominated the intraday game, but the volume cooperation was limited, constraining the rebound space, and the signals from large orders were scattered. Overall, a new round of regulatory details for the pharmaceutical industry is about to be released, becoming a key focus for the market and significantly impacting the sector's trend. The risk exposure cannot be ignored; if negative news arises or if the main operators significantly reduce their holdings, the pressure will intensify. It is recommended to continue monitoring policy dynamics and changes in hotspots within the pharmaceutical sector, dynamically managing positions to cope with uncertainties

Technical Forecast·02/04/2026 09:00

Technical Forecast·02/04/2026 09:00

Nucleai's AI tech aids lung cancer study in Nature Communications, focused on NSCLC immunotherapy response.

Nucleai, an Israeli company specializing in AI-powered multimodal spatial biology, has revealed its involvement in a joint international research project featured in Nature Communications. The study, conducted by academic experts from The University of Queensland and Yale School of Medicine, delves into the correlation between the spatial arrangement and metabolic attributes of tumor cells and their reaction to immunotherapy in non-small cell lung cancer (NSCLC). Published results shed light on the significance of these factors in treatment response.

Unusual Whales·02/04/2026 04:34